This trial is testing Ruxolitinib as a possible treatment for Myelofibrosis, a disorder where the bone marrow doesn't make enough blood cells.
1 Primary · 7 Secondary · Reporting Duration: 1 and 2 years
Side Effects for
Awards & Highlights
2 Treatment Groups
Ruxolitinib Not Eligible pre-HSCT
1 of 2
Ruxolitinib Eligible pre-HSCT
1 of 2
54 Total Participants · 2 Treatment Groups
Primary Treatment: Ruxolitinib Not Eligible pre-HSCT · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 75 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many people are total are enrolled in this clinical trial?
"Yes, this is an ongoing clinical trial that was originally posted on 8/28/2018. The latest update to the study's information was made on 10/21/2022. At present, 54 patients are being recruited from 5 different medical facilities." - Anonymous Online Contributor
Are patients currently being accepted for this clinical trial?
"The trial is currently ongoing, as seen on clinicaltrials.gov. Recruitment for the study began on 8/28/2018 and the most recent update was on 10/21/2022." - Anonymous Online Contributor
Does this study have any age requirements?
"For this particular clinical trial, patients between 18-75 years old are eligible to enroll. By comparison, there are 34 trials for patients younger than 18 and 195 trials for patients older than 65." - Anonymous Online Contributor
What type of patient would not be able to receive Ruxolitinib prior to a HSCT procedure?
"Ruxolitinib Not Eligible pre-HSCT is effective in treating polycythemia vera. This drug can also help patients with conditions like hydroxyurea resistance or intolerance, and primary myelofibrosis." - Anonymous Online Contributor
To whom is this clinical trial available?
"The ideal candidate for this clinical trial would be somebody suffering from primary myelofibrosis between the ages of 18 and 75. So far, 54 people have met the qualifications and enrolled in the study." - Anonymous Online Contributor
Would you be able to share how many hospitals are a part of this research?
"There are 4 primary centres for this trial. They are Vanderbilt University, Washington University, The Ohio State University Wexner Medical Center, and 5 other locations." - Anonymous Online Contributor
How does Ruxolitinib Not Eligible pre-HSCT affect patients?
"While there is some evidence supporting the safety of Ruxolitinib, it did not yet receive a score of 3 because Phase 2 trials have limited data on efficacy." - Anonymous Online Contributor
Are there other cases where Ruxolitinib wasn't effective in treating patients before a stem cell transplant?
"Ruxolitinib was first studied in 2002 at the National Institutes of Health Clinical Center. As of now, there are 92 completed trials and 99 live clinical trials studying this medication. A large portion of these studies are based in Nashville, Tennessee." - Anonymous Online Contributor